Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KCNA3 | P22001 | 11/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439284 | 0.94 | SLC6A9 (0.89) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL6435617 | 0.94 | SLC6A9 (0.89) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL2883643 | 0.90 | SLC6A9 (0.81) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL5585169 | 0.89 | SLC6A9 (0.80) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL5585095 | 0.89 | SLC6A9 (0.80) | SLC6A9MEN1KMT2AALDH1A1 | |
| SCHEMBL2469658 | 0.88 | SLC6A9 (0.78) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL2470690 | 0.88 | SLC6A9 (0.78) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL5591008 | 0.87 | SLC6A9 (0.77) | SLC6A9 | |
| SCHEMBL2471816 | 0.87 | SLC6A9 (0.76) | SLC6A9MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL2699889 | 0.86 | SLC6A9 (0.76) | SLC6A9MEN1KMT2AALDH1A1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017094025-A1 | METHOD OF IDENTIFICATION OF COMBINATORIAL ENZYMATIC REACTION TARGETS IN GLIOBLASTOMA SPECIFIC METABOLIC NETWORK | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-08 | — | — | WO | disclosed |
| EP-1126849-A4 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6303637-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, PROPHYLAXIS OF RESISTANCE TO TRANSPLANTATION OR TRANSPLANTATION REJECTION OF ORGANS OR TISSUES; SUPPRESSING IMMUNE SYSTEM | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| EP-1126849-A1 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025786-A1 | HETEROCYCLIC POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |